Clinical trial
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
NCT00184548 · Novo Nordisk A/S, Industry · Terminated
Key facts
| NCT number | NCT00184548 |
|---|---|
| Title | Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding |
| Official title | A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/NiaStase®) in Severely Injured Trauma Patients With Bleeding Refractory to Standard Treatment |
| Acronym | CONTROL |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acquired Bleeding Disorder, Trauma |
| Intervention type | Drug |
| Interventions | eptacog alfa (activated), placebo |
| Enrollment | 554 |
| Start date | Oct 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Sep 16, 2005 |
| Last update posted | Jun 25, 2014 |
| Countries | Brazil, Czechia, France, Germany, Greece, Hong Kong, Hungary, Italy, Netherlands, South Africa, Spain, Switzerland and 2 more |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: